VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PBYI
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PBYIPuma Biotechnology, Inc.
$7.34$374M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksPBYIBalance Sheet

Puma Biotechnology, Inc. (PBYI) Balance Sheet

19Y historyFree accessUpdated daily

The balance sheet has strengthened dramatically, with total debt reduced by over 95% from its peak to just $4.8M in Q2 2026, resulting in a negligible debt-to-equity ratio of 0.03 and virtually eliminating financial leverage risk.

Income StatementBalance SheetCash FlowRatios

PBYI Balance Sheet

Annual statement

PBYI Balance Sheet

Puma Biotechnology, Inc. (PBYI) balance sheet — 19-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Total Current Assets108.5M162.69M147.66M156.19M134.28M140.02M146.14M166.3M203M106.39M236.47M223.55M149.38M96.4M148.97M53.66M4622.41K731.41M
Cash & Short-Term Investments108.5M97.53M100.97M95.94M81.07M82.11M93.39M111.64M108.4M81.7M194.5M31.6M38.5M83.95M137.4M53.38M4622.41K731.41M
Cash Only41.5M29.64M69.22M84.58M76.2M63.13M85.29M60.04M108.4M81.7M194.5M31.6M38.5M43.04M137.4M53.38M4622.41K731.41M
Short-Term Investments67M67.89M31.75M11.35M4.87M18.98M8.1M51.61M0000040.9M000000
Accounts Receivable053.65M32.01M48.49M42.27M32.53M25.54M28.9M21.95M9.67M001.76M9.81M10.61M00000
Days Sales Outstanding44.8885.7550.775.1167.6646.941.4238.7431.92127.42----------
Inventory05.51M8.72M7.08M4.53M7.11M3.45M3.17M2.63M2.03M00102.83M08K00000
Days Inventory Outstanding41.0334.6149.4441.2329.9940.7332.0231.4327.69132.25----------
Other Current Assets04M3.7M260K1.95M11.43M11.75M11.74M3.85M11.69M005.29M2.08M0281.1K0000
Total Non-Current Assets053.62M65.67M74.34M87.78M86.56M98.08M68.61M56.12M59.13M16.32M16.29M13.38M7.98M2.73M1.74M0000
Property, Plant & Equipment05.56M5.09M8.65M12.51M15.77M18.89M21.83M3.96M4.47M5.15M2.38M2.16M1.68M1.48M682.05K0000
Fixed Asset Turnover62.75x41.07x45.24x27.25x18.23x16.05x11.92x12.47x63.34x6.20x------0.41x----
Goodwill00000000000000000000
Intangible Assets041.39M51.13M60.87M70.61M66.13M74.14M40.46M44.41M48.35M0000000000
Long-Term Investments0002.09M00002K4.32M4.32M4.31M00000000
Other Non-Current Assets02.83M2.38M2.73M4.66M4.67M5.06M6.32M6.01M6.31M6.85M9.6M11.22M6.29M1.25M1.05M0000
Total Assets108.5M216.3M213.33M230.53M222.06M226.59M244.22M234.91M259.12M165.53M252.79M239.84M162.76M104.37M151.7M55.4M4622.41K731.41M
Asset Turnover1.31x1.06x1.08x1.02x1.03x1.12x0.92x1.16x0.97x0.17x------0.01x----
Asset Growth %-48.02%1.39%-7.46%3.81%-2%-7.22%3.97%-9.35%56.55%-34.52%5.4%47.36%55.94%-31.2%-11990845.24%-80.81%3198.63%-99.99%-
Total Current Liabilities081.25M96.11M99.38M77.48M109.59M114.25M90.84M67.11M58.34M37.46M32.44M44.44M19.27M21.7M586.21K02.27K2.25K0
Accounts Payable05.06M5.51M6.89M6.44M11.17M12.08M19.18M20.68M27.69M20.04M17.8M15M10.69M482K86.67K02.27K2.25K0
Days Payables Outstanding24.3331.7331.2240.1142.6764.03111.95190.19218.21.8K6.36K8.37K--------
Short-Term Debt022.52M45.33M34M0014.29M0000000000000
Deferred Revenue (Current)00000000000000000000
Other Current Liabilities016.5M15.18M43.42M13.34M11.22M15.09M5.76M40.29M27.85M0010.58M020.43M190.61K0000
Current Ratio-2.00x1.54x1.57x1.73x1.28x1.28x1.83x3.02x1.82x6.31x6.89x3.36x5.00x6.86x91.54x-1.06x0.03x-
Quick Ratio-1.93x1.45x1.50x1.67x1.21x1.25x1.80x2.99x1.79x6.31x6.89x1.05x5.00x6.86x91.54x-1.06x0.03x-
Cash Conversion Cycle61.5888.6368.9276.2254.9823.6-38.51-120.02-158.59-1.55K----------
Total Non-Current Liabilities04.71M25.1M77.7M122.97M119.44M135.92M126.61M157.7M53.88M5.5M1.39M1.27M1.12M1.09M439.42K0000
Long-Term Debt0021.72M65.66M98.31M97.09M84.03M94.96M151.89M48.48M0000000000
Capital Lease Obligations13.62M4.71M1.49M7.03M11.83M15.97M19.55M22.64M000000000000
Deferred Tax Liabilities00000000000000000000
Other Non-Current Liabilities001.88M5.01M12.83M6.38M32.34M9M5.82M5.41M5.5M1.39M1.27M1.12M1.09M439.42K0000
Total Liabilities085.96M121.21M177.09M200.45M229.03M250.17M217.44M224.82M112.22M42.97M33.84M45.71M20.39M22.79M1.03M02.27K2.25K1.41M
Total Debt028.55M74.08M111.49M114.28M116.64M120.95M120.23M151.89M48.48M0000000000
Net Debt-41.5M-1.09M4.86M26.91M38.08M53.51M35.66M60.19M43.49M-33.22M-194.5M-31.6M-38.5M-43.04M-137.4M-53.38M-462-2.41K-73-1.41M
Debt / Equity-0.22x0.80x2.09x5.29x--6.88x4.43x0.91x----------
Debt / EBITDA0.00x0.59x1.74x2.52x3.41x9.26x--------------
Net Debt / EBITDA-1.22x-0.02x0.11x0.61x1.13x4.25x--------------
Interest Coverage11.80x6.40x2.94x2.70x1.04x-1.25x-3.26x-4.03x-9.33x-404.49x-288.72x-247.46x-439.12x-318.80x-758.69x-2704.96x----
Total Equity0130.34M92.13M53.44M21.61M-2.45M-5.95M17.46M34.31M53.3M209.8M206M117M83.99M128.9M54.37M462138-2.18K1.41M
Equity Growth %6.02%41.48%72.38%147.33%983.4%58.9%-134.08%-49.1%-35.64%-74.59%1.84%76.07%39.31%-34.84%-11768846.97%234.78%106.34%-100.15%-
Book Value per Share0.002.571.881.120.48-0.06-0.150.450.901.436.306.413.902.935.932.710.000.00-0.000.04
Total Shareholders' Equity0130.34M92.13M53.44M21.61M-2.45M-5.95M17.46M34.31M53.3M209.8M206M117M83.99M128.9M54.37M462138-2.18K1.41M
Common Stock05K5K5K5K4K4K4K4K4K4K3K3K3K3K2K300300300300K
Retained Earnings0-1.28B-1.31B-1.35B-1.37B-1.37B-1.34B-1.28B-1.2B-1.09B-796.51M-520.5M-281.22M-139.25M-84.59M-10.24M-61.99K-46.01K-29.18K0
Treasury Stock00000000000000000000
Accumulated OCI036K6K-4K0-2K062K-12K-449K-13K-147K-95K3K-276K-10.7K0000
Minority Interest00000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Persistent negative retained earnings

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Deleveraging Drives Balance Sheet Strength

PBYI's balance sheet has strengthened dramatically, with total debt declining from $110.7M in Q1 2024 to just $4.8M in Q2 2026, while equity has grown from $51.0M to $138.5M, indicating a successful deleveraging cycle.

The trajectory shows a clear and consistent improvement in financial health, driven by the systematic reduction of debt and the accumulation of equity. This deleveraging has been the primary driver of the balance sheet's transformation from a leveraged position (D/E of 2.17 in Q1 2024) to a nearly unleveraged one (D/E of 0.03 in Q2 2026). The pattern suggests the company has prioritized strengthening its financial foundation, which may provide greater operational flexibility and reduce refinancing risk.

Near-Elimination of Financial Leverage

Total debt has been reduced by over 95% from its peak, falling to $4.8M in Q2 2026, resulting in a negligible debt-to-equity ratio of 0.03 and virtually eliminating interest rate and refinancing risk.

The debt profile has shifted from a material liability to a trivial one, with the D/E ratio collapsing from 2.17 to 0.03 over ten quarters. This suggests the company has used its cash flows to retire obligations rather than fund growth, indicating a conservative financial strategy. The minimal remaining debt implies that future cash flows are largely unencumbered by interest payments, though it also raises questions about the company's appetite for leverage to fund potential expansion.

Robust Liquidity Buffer Despite Cash Decline

While cash has decreased from $76.8M to $36.5M over the period, the current ratio has improved to a strong 2.91, indicating ample short-term liquidity and a substantial buffer against operational shocks.

The improvement in the current ratio, despite a lower cash balance, is driven by a more significant reduction in current liabilities. This suggests the company has been actively managing its working capital and short-term obligations. The $36.5M cash position, while lower than its peak, still represents a meaningful runway relative to the company's operating cost structure, providing stability amid the revenue volatility noted in prior analysis.

Goodwill Dominance and Asset-Light Profile

Goodwill constitutes approximately 19% of total assets at $36.5M, while net PPE is minimal at $4.5M, highlighting an asset-light model where value is concentrated in intangible assets.

The asset mix reveals a business model heavily reliant on intellectual property and acquired intangibles rather than physical infrastructure. The steady decline in goodwill from $58.4M to $36.5M suggests either amortization or impairment charges, which warrants monitoring for potential future write-downs. The low PPE base indicates limited capital intensity, which aligns with the biotechnology sector but also means the tangible asset cushion is thin.

Equity Growth Masked by Deep Retained Deficit

Total equity has grown to $138.5M, yet this is built upon a massive accumulated deficit of approximately $1.3B in retained earnings, indicating that equity growth is driven by paid-in capital rather than operational profitability.

The stark contrast between positive total equity and the deeply negative retained earnings balance is the most critical feature of PBYI's equity structure. It implies the company has historically consumed far more capital than it has generated through profits, relying on external financing to fund operations and growth. The recent growth in equity, therefore, appears to stem from new capital contributions or other comprehensive income, not from the retention of earnings, which challenges the sustainability of the equity base without continued external support.

The Illusion of Equity Strength

The headline equity figure of $138.5M is fundamentally misleading, as it is entirely offset by a $1.3B accumulated deficit, revealing that the company's net asset value is derived from investor capital, not earned profits.

This is the single most important distortion in PBYI's balance sheet. While the D/E ratio and current ratio suggest a healthy, low-risk profile, the underlying equity quality is poor. The negative retained earnings indicate a long history of net losses, meaning the company has not yet proven it can generate sustainable profits to build intrinsic book value. Investors should focus on the trajectory of the retained earnings deficit; a narrowing would be a far more meaningful signal of financial health improvement than further debt reduction.

PBYI — Frequently Asked Questions

Quick answers to the most common questions about buying PBYI stock.

What are the total assets of Puma Biotechnology, Inc. (PBYI)?

As of 2025, Puma Biotechnology, Inc. (PBYI) had total assets of $216.3M including $162.7M in current assets.

How much debt does Puma Biotechnology, Inc. (PBYI) have?

Puma Biotechnology, Inc. (PBYI) carries total debt of $28.5M, offset by $97.5M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Puma Biotechnology, Inc.?

Puma Biotechnology, Inc. (PBYI) has total shareholders' equity (book value) of $130.3M ($2.57 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Puma Biotechnology, Inc.'s current ratio and liquidity?

Puma Biotechnology, Inc. (PBYI) reported a current ratio of 2.00x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.